<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170504</url>
  </required_header>
  <id_info>
    <org_study_id>2018YFC1705203</org_study_id>
    <nct_id>NCT04170504</nct_id>
  </id_info>
  <brief_title>Efficacy of Chinese Herbal Medicine Qing Re Huo Xue in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>Efficacy of Chinese Herbal Medicine Qing Re Huo Xue in Patients With Rheumatoid Arthritis: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, double-blinded, controlled trial with two parallel
      arms. The aim of the study is to evaluate whether Chinese herbal medicine Qing Re Huo Xue
      (QRHX) combined with methotrexate (MTX) might be better than MTX alone for patients with
      active rheumatoid arthritis (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy and safety of Chinese herbal medicine Qing Re Huo Xue (QRHX) and
      methotrexate (MTX) for patients with active rheumatoid arthritis (RA), a multicenter,
      randomized controlled trial will be conducted. Two hundred and four patients with active RA
      will be randomly allocated (1:1) to treatment with QRHX 10mg bid and MTX 10 mg once a week
      for 24 weeks, or MTX plus dummy QRHX. The primary outcome is he OMERACT rheumatoid arthritis
      MRI scoring system (RAMRIS) at week 24.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in OMERACT RAMRIS</measure>
    <time_frame>week 24</time_frame>
    <description>Bone erosions will be assessed by OMERACT-RAMRIS scoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of ACR20</measure>
    <time_frame>week 24</time_frame>
    <description>Percentage of Participants With American College of Rheumatology 20% (ACR20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of ACR50</measure>
    <time_frame>week 24</time_frame>
    <description>Percentage of Participants With American College of Rheumatology 50% (ACR50)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of ACR70</measure>
    <time_frame>week 24</time_frame>
    <description>Percentage of Participants With American College of Rheumatology 70% (ACR70)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Total Sharp X-Ray Score at Week 24</measure>
    <time_frame>week 24</time_frame>
    <description>Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chinese Patient-reported Activity Index with RA scale (PRO)</measure>
    <time_frame>week 24</time_frame>
    <description>Patient-Reported Outcomes Scale,The self-rating scale consists of 12 items,Each item was rated 0, 1, 2 and 3 on the scale of asymptomatic to aggravating symptoms, respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Qing Re Huo Xue (QRHX) plus methotrexate (MTX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QRHX XXmg bid and methotrexate (MTX) 10 mg once a week for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qing Re Huo Xue (QRHX)</intervention_name>
    <description>Qing Re Huo Xue (QRHX) XXmg bid for 24 weeks</description>
    <arm_group_label>Qing Re Huo Xue (QRHX) plus methotrexate (MTX)</arm_group_label>
    <other_name>GAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Oral methotrexate 10 mg per week for 24 weeks.</description>
    <arm_group_label>Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)</arm_group_label>
    <arm_group_label>Qing Re Huo Xue (QRHX) plus methotrexate (MTX)</arm_group_label>
    <other_name>XINYI Pharm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dummy Qing Re Huo Xue (QRHX)</intervention_name>
    <description>dummy Qing Re Huo Xue (QRHX) XXmg bid for 24 weeks</description>
    <arm_group_label>Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)</arm_group_label>
    <other_name>GAM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has had a confirmed diagnosis of rheumatoid arthritis according to 2010
             ACR/EULAR RA classification criteria.

          2. Subject has a DAS28 CRP disease activity score of &gt;3.2 at screening.

          3. Subject also experienced the following signs and symptoms: swelling, joint pain, and
             heat in the joints.

          4. Subject has had no prior exposure to oral glucocorticoids at a daily dose greater than
             10 mg or to any biologic agents.

          5. Subject may has had previous exposure to nonsteroidal anti-inflammatory drugs (NSAIDs)
             prior to screening and must be on stable dose.

        Exclusion Criteria:

          1. History or presence of a clinically significant medical disorder other than RA that,
             in the opinion of the investigator and medical monitor, would pose a risk to subject
             safety or interfere with the study evaluation, procedures, or completion.

          2. Subject has inflammatory, rheumatological disorders other than RA, where arthritis may
             be a prominent feature.

          3. Subject has received treatment with the prohibited therapies listed in the protocol,
             or changes to those treatments, within the prescribed timeframe.

          4. Pregnant or nursing an infant or with a life partner who is pregnant, nursing, or
             planning to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quan Jiang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guang' anmen hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quan Jiang, M.D</last_name>
    <phone>+8613901081632</phone>
    <phone_ext>0</phone_ext>
    <email>doctorjq@126.com</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Quan Jiang</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Qing Re Huo Xue</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

